Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Castle Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Castle Biosciences, Inc.’s stock price such as:

• Castle Biosciences, Inc.’s current stock price and volume
• Why Castle Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for CSTL from analysts
• CSTL’s stock price momentum as measured by its relative strength

About Castle Biosciences, Inc. (CSTL)

Before we jump into Castle Biosciences, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Want to learn more about Castle Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Castle Biosciences, Inc..

Castle Biosciences, Inc.’s Stock Price as of Market Close

As of April 15, 2026, 3:09 PM, CST, Castle Biosciences, Inc.’s stock price was $24.660.

Castle Biosciences, Inc. is up 1.19% from its previous closing price of $24.370.

During the last market session, Castle Biosciences, Inc.’s stock traded between $24.370 and $25.000. Currently, there are approximately 29.33 million shares outstanding for Castle Biosciences, Inc..

Castle Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Castle Biosciences, Inc. Stock Price History

Castle Biosciences, Inc.’s (CSTL) price is currently up 0.45% so far this month.

During the month of April, Castle Biosciences, Inc.’s stock price has reached a high of $26.680 and a low of $21.790.

Over the last year, Castle Biosciences, Inc. has hit prices as high as $44.280 and as low as $14.590. Year to date, Castle Biosciences, Inc.’s stock is down 36.61%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Castle Biosciences, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 14, 2026, there were 2 analysts who downgraded Castle Biosciences, Inc.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Castle Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Castle Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Castle Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Castle Biosciences, Inc. (CSTL) by visiting AAII Stock Evaluator.

Relative Price Strength of Castle Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 14, 2026, Castle Biosciences, Inc. has a weighted four-quarter relative price strength of -3.07%, which translates to a Momentum Score of 40 and is considered to be Weak.

Want to learn more about how Castle Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Castle Biosciences, Inc. Stock Price: Bottom Line

As of April 15, 2026, Castle Biosciences, Inc.’s stock price is $24.660, which is up 1.19% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Castle Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.